Regeneration / Research index
KPV
KPV is the tripeptide lysine-proline-valine. Its intestinal research highlights the distinction between a compound, its transport pathway and a tested formulation.
Names used in the literature: KPV · Lys-Pro-Val · Lysine-proline-valine
Read the evidence and its sources ↓That presentation is not part of this listing. Review the available options before adding a selection.
KPV 5 mg
- Presentation
- 5 mg
- Catalog reference
- PMX-KPV-10
Availability and documentation await confirmation. Listed quantities identify catalog presentations, not instructions for use.
Cellular transport and signaling
A 2008 study examined KPV in intestinal and immune cell lines and two mouse colitis models. It linked cellular uptake to PepT1 and found reduced activation of NF-κB and MAPK signaling. This was not a clinical-effectiveness trial in patients.
Sources: [1]
Formulation is part of the experiment
A 2017 study evaluated KPV within hyaluronic-acid-functionalized nanoparticles and a hydrogel. Mucosal damage and inflammation were examined in mice. Those findings belong to the complete delivery system; they do not establish the same behavior for a KPV catalog entry without that vehicle.
Sources: [2]
Questions about this reference
Is KPV the name of a nanoparticle formulation?
No. The 2017 study incorporated KPV into a specific delivery system, distinct from the peptide itself.
Does the colitis model demonstrate a human treatment?
No. The cited cellular and mouse findings do not establish clinical effectiveness in people.
Sources and original reading
- PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation
- Orally Targeted Delivery of Tripeptide KPV via Hyaluronic Acid-Functionalized Nanoparticles Efficiently Alleviates Ulcerative Colitis
Content updated: . How this content is prepared and checked.
Understand before comparing